65,437 trials
Actinic Keratosis
Primary: Percentage of Participants With Complete Clearance of Actinic Keratosis (AK) — 22.0; 3.0 percentage of participants — p=<0.001
Depression
Primary: Hamilton Rating Scale for Depression — 11.06; 12.52 units on a scale
CD20+, B-cell Lymphomas · Mantle Cell Lymphoma · Non-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL)
Primary: Safety as Assessed by Avoidance of Grade 3-4 Adverse Events — 1 Participants
Psoriasis
Primary: Percentage of Participants Who Experienced Psoriasis Relapse (Treating Drop-Outs as Relapse) — 91.1; 87.0; 55.6; 30.4 percentage of participants — p=0.41
Amyotrophic Lateral Sclerosis
Primary: Duration of Day Time Wear Time of the Device — 718.536; 730.882; 653.980; 207.263 Minutes
Heart Disease
Primary: SF-36v Physical Function Scale — -6.67; 13.33 units on a scale
Lambert-Eaton Myasthenic Syndrome
Primary: Quantitative Myasthenia Gravis (QMG) Score — 7.8; 8.5; 7.9; 15.0 scores on a scale — p=0.0004
Metastatic Colorectal Cancer
Primary: Overall Survival (OS) Time — 7.9; 10.3; 9.6 months
Intra-Abdominal Infections · Skin Disease, Infectious
Primary: Number of Participants With Adverse Drug Reaction (ADR) — 41; 15 Participants
Osteoporosis
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 209; 17 Participants
Menstruation Disturbances
Primary: Ovulation in Cycle 2 — 3; 2 Participants
Colorectal Cancer
Primary: The Number of Participants Who Completed the Mailed FIT Test Screening Within 6 Months — 0; 0; 62 Participants
Dental White Spots · Dental Caries
Primary: Change in White Spot Lesions Count - Enamel Decalcification Index (EDI) — 40.2; 41.3 units on a scale
Pediatrics · Solid Tumors
Primary: Maximum Tolerated Dose (MTD) of Eribulin Mesylate — 1.4 mg/m^2
Overactive Bladder (OAB)
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 131; 135; 133; 120 Participants